JAK2-V617F与BCR-ABL——双重风险？ - Suppr

Suppr

超能文献

JAK2-V617F and BCR-ABL--double jeopardy?

作者信息

Krämer Alwin

出版信息

Leuk Res. 2008 Oct;32(10):1489-90. doi: 10.1016/j.leukres.2008.03.011. Epub 2008 Apr 24.

DOI:10.1016/j.leukres.2008.03.011

PMID:18439674

Abstract

摘要

相似文献

JAK2-V617F and BCR-ABL--double jeopardy?

Leuk Res. 2008 Oct;32(10):1489-90. doi: 10.1016/j.leukres.2008.03.011. Epub 2008 Apr 24.

Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.

Leukemia. 2007 Sep;21(9):2051; author reply 2052. doi: 10.1038/sj.leu.2404825. Epub 2007 Jun 28.

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

Leukemia. 2008 May;22(5):1059-62. doi: 10.1038/sj.leu.2404993. Epub 2007 Nov 1.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.

Int J Lab Hematol. 2013 Feb;35(1):e4-5. doi: 10.1111/ijlh.12010. Epub 2012 Oct 13.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.

Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Int J Hematol. 2008 Sep;88(2):243-245. doi: 10.1007/s12185-008-0131-2. Epub 2008 Jul 16.

Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.

Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13.

Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Ann Lab Med. 2013 May;33(3):229-32. doi: 10.3343/alm.2013.33.3.229. Epub 2013 Apr 17.

Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.

Clin Lymphoma Myeloma. 2009 Oct;9(5):E25-9. doi: 10.3816/CLM.2009.n.080.

引用本文的文献

Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):331-4. doi: 10.1007/s12288-014-0385-1. Epub 2014 Apr 11.

Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Ann Lab Med. 2013 May;33(3):229-32. doi: 10.3343/alm.2013.33.3.229. Epub 2013 Apr 17.

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Genes Cancer. 2010 Oct;1(10):979-93. doi: 10.1177/1947601910397187.

A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Genes Cancer. 2010 Apr;1(4):331-45. doi: 10.1177/1947601910371337.

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Genome Med. 2009 May 29;1(5):55. doi: 10.1186/gm55.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验